IOncology

The “2025 Pujiang Prostate Cancer Academic Conference,” held from June 27 to 28 in Shanghai, was jointly organized with the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Chinese Anti-Cancer Association Genitourinary Oncology Committee (CACA-GO) Prostate Cancer Meeting, and the Annual Conference of the Chinese Prostate Cancer Consortium (CPCC). With the theme “Global Vision · Chinese Practice · Precision Breakthrough,” the event attracted numerous domestic and international experts to share the latest advances and real-world experiences in prostate cancer.

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting took place from May 30 to June 3 in Chicago. At this global event, Professor Yiding Chen from the Second Affiliated Hospital, Zhejiang University School of Medicine, presented results from the biomarker analysis of the DANCER study. Focusing on operable HER2-negative Luminal B breast cancer, the study explored biomarkers related to neoadjuvant dalpiciclib-based therapy, offering new perspectives for precision treatment. Oncology Frontier conducted an exclusive interview with Prof. Chen onsite at ASCO, where he detailed the background, findings, and clinical significance of the study—highlighting the crucial role biomarkers may play in predicting treatment response and opening new avenues for breast cancer care.

At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ESMO President-Elect Professor Giuseppe Curigliano of the European Institute of Oncology (IEO), Milan, Italy, presented findings from the patient-reported outcomes (PRO) analysis of the Phase III EMBER-3 trial. The data revealed changes in overall health status, quality of life, and physical function scores in patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer treated with either imlunestrant alone or in combination with abemaciclib. Oncology Frontier conducted an exclusive interview with Professor Curigliano at the conference to discuss the clinical applicability of imlunestrant monotherapy and its combination with abemaciclib, as well as their impact on patient quality of life—offering new perspectives for clinical practice.

Antibody–drug conjugates (ADCs) targeting HER2 have already transformed the treatment landscape in advanced breast cancer and are now making their way into early-stage settings. At the 2025 ASCO Annual Meeting, Professor Junjie Li from Fudan University Shanghai Cancer Center presented results from a phase II clinical study investigating a novel HER2 bispecific ADC, TQB2102, in the neoadjuvant treatment of HER2-positive early breast cancer. The study delivered striking pathological complete response (pCR) results, suggesting strong potential for clinical impact. Below is an on-site interview with Professor Li, summarizing the key findings.

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 30 to June 3. At the conference, Professor Ting Li of Fudan University Shanghai Cancer Center delivered a Rapid Oral Abstract presentation on behalf of her team, showcasing a phase II clinical study (Abstract #1018) titled "A phase II clinical study of adebrelimab and bevacizumab combined with cisplatin/carboplatin in triple-negative breast cancer patients with brain metastases." Following her presentation, Oncology Frontier conducted an exclusive interview with Professor Li, where she shared insights into the rationale behind the study design, the benefits of the triplet therapy, and the specific patient groups most likely to benefit.

A dynamic understanding of the tumor microenvironment (TME) is essential for uncovering the mechanisms behind treatment response and disease progression. At the 2025 ASCO Annual Meeting, Professor Jieqiong Liu from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, presented an innovative translational study (Abstract #1022) exploring the efficacy and safety of a novel combination therapy in patients with HER2-positive metastatic breast cancer who had failed second-line or later treatments. The team employed single-cell sequencing to analyze TME changes before and after treatment with KN046, a bispecific anti-CTLA-4/PD-L1 antibody, and KN026, a bispecific anti-HER2 antibody. The results revealed distinct immunological  differences between responders and non-responders and identified the baseline macrophage-to-lymphatic endothelial cell (Mϕ/LEC) ratio as a predictive biomarker of treatment response. This study offers new insights into individualized care strategies for breast cancer.

At the 2025 ASCO Annual Meeting, multiple cutting-edge oncology studies were presented. Among them were two studies led by Professor Biyun Wang from Fudan University Shanghai Cancer Center. One was a prospective, single-arm phase II clinical trial (Abstract #1101) evaluating the efficacy and safety of camrelizumab in combination with albumin-bound paclitaxel and cisplatin (the AP regimen) as a first-line treatment for metastatic triple-negative breast cancer (mTNBC). Results showed a median PFS of 11.8 months and median OS of 27.1 months, with manageable toxicity. The second study, an ongoing trial (Abstract #TPS1122), aims to predict treatment response to T-DXd in HER2-positive breast cancer brain metastases using68Ga-FAPI PET-CT to assess tumor metabolic heterogeneity. The trial is actively recruiting patients.This article specifically introduces two studies.